Pyxis Oncology, Inc. (PYXS) Stock

Pyxis Oncology, Inc. (PYXS) is a Healthcare stock trading at $3.07 (as of 2026-08-21), with a market capitalization of $256.06M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pyxis Oncology, Inc. is a preclinical-stage biopharmaceutical company developing cancer therapies across immune-oncology, including investigational antibodies and immuno-therapeutics such as PYX-106 and PYX-102, and antibody-drug conjugates including PYX-201, PYX-202, and PYX-203. Its candidates target multiple solid tumors and blood cancers.

Understand Pyxis Oncology, Inc.: how it makes money

Pyxis Oncology develops immune-oncology therapies for cancer, including antibody and antibody-drug conjugate candidates (such as PYX-106 and PYX-201), and it earns limited revenue through royalty rights and related royalty revenues (and potentially milestones).

The company’s near-term profit model is structurally driven by partnering-style cash flows, such as royalty revenues and royalty rights (rather than meaningful commercial product sales).

Revenue by segment (latest quarter)
Royalties	$0.0B
Milestones	$0.0B

Business quality (Weak): This is a preclinical-stage biopharma where the current revenue base appears small and is tied to royalty-type streams, while operating results are deeply loss-making. Key watch items are both the royalty cash flows and progress shown in clinical development metrics.

Bull case

Royalty-type revenue provides some external value capture: The company reports Royalty Revenues (and also has a related line for revenue from sale of royalty rights), which indicates some monetization of its IP or collaborations even at this stage.
Clinical development metrics are tracked across multiple candidates: Operational metrics provided include dosing activity for PYX-106 (subjects dosed to date) and PYX-201 (patients dosed and dose cohorts), which can help track execution toward future data.

Bear case

Operating losses are extremely large relative to revenue: For the latest reported period (2026-03-31), operating margin is -11174.3 while revenue_b is 0.0, indicating substantial losses versus any current revenue.
Revenue visibility may depend on non-operational monetization: The provided revenue lines are royalty rights and royalty revenues (plus milestone revenue at 0.0), which can be less predictable than recurring commercial sales and may not scale quickly if trials or commercialization progress.
Clinical and regulatory risk remains high at preclinical stage: Because the company is developing therapies for cancer and reports development-stage metrics, outcomes depend on trial results and subsequent regulatory and clinical validation.

Valuation — source: SEC EDGAR (first-party)
Price	$3.07
Market Cap	$256.06M
Price / Book	22.38
Price / Sales	346.50
FCF Yield	-20.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$13.86M
Net Margin	-574.5%
Revenue Growth (YoY)	-97.8%
EPS Growth (YoY)	33.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-5.97 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Pfizer Inc ($9.21M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Thomas Civik
Employees	44
Country	US
IPO Date	2021-10-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.